Cardiac impact of inhaled therapy in the largest randomised placebo-controlled trial in COPD history: have we reached the SUMMIT?
作者信息
Andreas Stefan, Janson Christer, van den Berge Maarten, Lahousse Lies
机构信息
Cardiology and Pneumology, University Medical Center Göttingen, Göttingen, Germany; Lung Clinic Immenhausen, Immenhausen, Germany.
Dept of Medical Sciences: Respiratory, Allergy and Sleep Research, Uppsala University, Uppsala, Sweden.
出版信息
ERJ Open Res. 2016 May 26;2(2). doi: 10.1183/23120541.00055-2016. eCollection 2016 Apr.
Abstract
摘要
相似文献
1
Cardiac impact of inhaled therapy in the largest randomised placebo-controlled trial in COPD history: have we reached the SUMMIT?
ERJ Open Res. 2016 May 26;2(2). doi: 10.1183/23120541.00055-2016. eCollection 2016 Apr.
2
Adding a LAMA to ICS/LABA Therapy: A Meta-analysis of Triple Combination Therapy in COPD.在 ICS/LABA 治疗中添加 LAMA：COPD 三联疗法的荟萃分析。
Chest. 2019 Apr;155(4):758-770. doi: 10.1016/j.chest.2018.12.016. Epub 2019 Jan 17.
3
The effect of umeclidinium added to inhaled corticosteroid/long-acting β2-agonist in patients with symptomatic COPD: a randomised, double-blind, parallel-group study.在有症状的 COPD 患者中，乌美溴铵联合吸入性皮质类固醇/长效β2-激动剂的疗效：一项随机、双盲、平行分组研究。
NPJ Prim Care Respir Med. 2016 Jun 23;26:16031. doi: 10.1038/npjpcrm.2016.31.
4
Intensified Therapy with Inhaled Corticosteroids and Long-Acting β-Agonists at the Onset of Upper Respiratory Tract Infection to Prevent Chronic Obstructive Pulmonary Disease Exacerbations. A Multicenter, Randomized, Double-Blind, Placebo-controlled Trial.上呼吸道感染发作时强化吸入皮质类固醇和长效β激动剂治疗预防慢性阻塞性肺疾病加重的多中心、随机、双盲、安慰剂对照试验。
Am J Respir Crit Care Med. 2018 May 1;197(9):1136-1146. doi: 10.1164/rccm.201709-1807OC.
5
Risk of Cardiovascular Events Associated with Inhaled Corticosteroid Treatment in Patients with Chronic Obstructive Pulmonary Disease: A Meta-Analysis.慢性阻塞性肺疾病患者吸入糖皮质激素治疗相关的心血管事件风险：一项荟萃分析。
Can Respir J. 2018 Jul 15;2018:7097540. doi: 10.1155/2018/7097540. eCollection 2018.
6
Inhaled corticosteroids versus long-acting beta(2)-agonists for chronic obstructive pulmonary disease.吸入性糖皮质激素与长效β₂受体激动剂治疗慢性阻塞性肺疾病的比较
Cochrane Database Syst Rev. 2011 Oct 5(10):CD007033. doi: 10.1002/14651858.CD007033.pub2.
7
Comparative safety of inhaled medications in patients with chronic obstructive pulmonary disease: systematic review and mixed treatment comparison meta-analysis of randomised controlled trials.比较慢性阻塞性肺疾病患者吸入药物的安全性：随机对照试验的系统评价和混合治疗比较荟萃分析。
Thorax. 2013 Jan;68(1):48-56. doi: 10.1136/thoraxjnl-2012-201926. Epub 2012 Oct 6.
8
Effect of lung deflation with indacaterol plus glycopyrronium on ventricular filling in patients with hyperinflation and COPD (CLAIM): a double-blind, randomised, crossover, placebo-controlled, single-centre trial.茚达特罗加格隆溴铵对肺气肿充气过度合并 COPD 患者心室充盈的影响（CLAIM）：一项双盲、随机、交叉、安慰剂对照、单中心试验。
Lancet Respir Med. 2018 May;6(5):368-378. doi: 10.1016/S2213-2600(18)30054-7. Epub 2018 Feb 21.
9
Long-acting beta2-agonists versus anti-leukotrienes as add-on therapy to inhaled corticosteroids for chronic asthma.长效β2受体激动剂与抗白三烯药物作为吸入性糖皮质激素治疗慢性哮喘的附加疗法比较
Cochrane Database Syst Rev. 2005 Jan 25(1):CD003137. doi: 10.1002/14651858.CD003137.pub2.
10
Long-acting beta2-agonists versus anti-leukotrienes as add-on therapy to inhaled corticosteroids for chronic asthma.长效β2受体激动剂与抗白三烯药物作为吸入性糖皮质激素治疗慢性哮喘的附加疗法比较
Cochrane Database Syst Rev. 2006 Oct 18(4):CD003137. doi: 10.1002/14651858.CD003137.pub3.
引用本文的文献
1
COPD mortality and exacerbations in the placebo group of clinical trials over two decades: a systematic review and meta-regression.二十年来临床试验安慰剂组中的慢性阻塞性肺疾病死亡率和急性加重：一项系统评价和Meta回归分析
ERJ Open Res. 2022 Mar 7;8(1). doi: 10.1183/23120541.00261-2021. eCollection 2022 Jan.
2
Impact of pre-enrolment medication use on clinical outcomes in SUMMIT.入组前用药对SUMMIT研究临床结局的影响。
ERJ Open Res. 2019 Feb 25;5(1). doi: 10.1183/23120541.00203-2018. eCollection 2019 Feb.
本文引用的文献
1
Fluticasone furoate and vilanterol and survival in chronic obstructive pulmonary disease with heightened cardiovascular risk (SUMMIT): a double-blind randomised controlled trial.氟替卡松酯和维兰特罗与心血管风险升高的慢性阻塞性肺疾病患者的生存关系（SUMMIT）：一项双盲随机对照试验。
Lancet. 2016 Apr 30;387(10030):1817-26. doi: 10.1016/S0140-6736(16)30069-1. Epub 2016 Apr 28.
2
Blood eosinophils as a marker of response to inhaled corticosteroids in COPD.血嗜酸性粒细胞作为 COPD 患者吸入皮质类固醇激素反应的标志物。
Eur Respir J. 2016 May;47(5):1374-82. doi: 10.1183/13993003.01370-2015. Epub 2016 Feb 25.
3
Comparative Cardiovascular and Cerebrovascular Safety of Inhaled Long-Acting Bronchodilators in Patients with Chronic Obstructive Pulmonary Disease: A Population-Based Cohort Study.慢性阻塞性肺疾病患者吸入长效支气管扩张剂的心血管和脑血管安全性比较：一项基于人群的队列研究。
Pharmacotherapy. 2016 Jan;36(1):26-37. doi: 10.1002/phar.1684.
4
Cardiac effects of current treatments of chronic obstructive pulmonary disease.慢性阻塞性肺疾病治疗的心脏效应。
Lancet Respir Med. 2016 Feb;4(2):149-64. doi: 10.1016/S2213-2600(15)00518-4. Epub 2016 Jan 12.
5
Efficacy and safety of long-acting β-agonist/long-acting muscarinic antagonist combinations in COPD: a network meta-analysis.长效β-激动剂/长效毒蕈碱拮抗剂联合治疗 COPD 的疗效和安全性：一项网络荟萃分析。
Thorax. 2016 Jan;71(1):15-25. doi: 10.1136/thoraxjnl-2014-206732. Epub 2015 Oct 21.
6
Risk of cardiovascular comorbidity in patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis.慢性阻塞性肺疾病患者心血管合并症的风险：系统评价和荟萃分析。
Lancet Respir Med. 2015 Aug;3(8):631-9. doi: 10.1016/S2213-2600(15)00241-6. Epub 2015 Jul 22.
7
Lung Volume Reduction Surgery and Improvement of Endothelial Function and Blood Pressure in Patients with Chronic Obstructive Pulmonary Disease. A Randomized Controlled Trial.肺减容手术对慢性阻塞性肺疾病患者内皮功能和血压的改善作用：一项随机对照试验。
Am J Respir Crit Care Med. 2015 Aug 1;192(3):307-14. doi: 10.1164/rccm.201503-0453OC.
8
Statement on smoking cessation in COPD and other pulmonary diseases and in smokers with comorbidities who find it difficult to quit.COPD 和其他肺部疾病以及患有合并症的吸烟者戒烟困难者的戒烟声明。
Eur Respir J. 2015 Jul;46(1):61-79. doi: 10.1183/09031936.00092614. Epub 2015 Apr 16.
9
Blood eosinophil counts, exacerbations, and response to the addition of inhaled fluticasone furoate to vilanterol in patients with chronic obstructive pulmonary disease: a secondary analysis of data from two parallel randomised controlled trials.血液嗜酸性粒细胞计数、加重情况以及慢性阻塞性肺疾病患者添加吸入氟替卡松维兰特罗后的反应：两项平行随机对照试验数据的二次分析。
Lancet Respir Med. 2015 Jun;3(6):435-42. doi: 10.1016/S2213-2600(15)00106-X. Epub 2015 Apr 12.
10
Asthma-COPD overlap. Clinical relevance of genomic signatures of type 2 inflammation in chronic obstructive pulmonary disease.哮喘-慢性阻塞性肺疾病重叠综合征。慢性阻塞性肺疾病中2型炎症基因组特征的临床相关性。
Am J Respir Crit Care Med. 2015 Apr 1;191(7):758-66. doi: 10.1164/rccm.201408-1458OC.
Zotero 插件